story of the week
Adjuvant Sunitinib or Sorafenib for High-Risk, Non-Metastatic Renal-Cell Carcinoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Adjuvant Sunitinib or Sorafenib for High-Risk, Non-Metastatic Renal-Cell Carcinoma (ECOG-ACRIN E2805): A Double-Blind, Placebo-Controlled, Randomised, Phase 3 Trial
Lancet 2016 Mar 08;[EPub Ahead of Print], NB Haas, J Manola, RG Uzzo, KT Flaherty, CG Wood, C Kane, M Jewett, JP Dutcher, MB Atkins, M Pins, G Wilding, D Cella, L Wagner, S Matin, TM Kuzel, WJ Sexton, YN Wong, TK Choueiri, R Pili, I Puzanov, M Kohli, W Stadler, M Carducci, R Coomes, RS DiPaolaFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.